No Evidence for an Association Between the Chemokine Receptor 5 Δ32 Polymorphism and Multiple Sclerosis Susceptibility: A Meta-Analysis
CCR5-Δ32 and MS, meta-analysis
Abstract
Background/Aim: Numerous reports have been published on the association of the chemokine receptor 5 Δ32 genetic variation (rs333) with the risk of multiple sclerosis (MS), with results that are inconsistent. The relationship between rs333 and susceptibility to MS was evaluated in this study.
Methods: The PRISMA guidelines were followed in the current study. Twelve databases were used to find eligible articles. The investigators extracted the necessary information. The associations of the alleles and genotypes were evaluated in different models of inheritance: co-dominant, dominant and recessive genotype models and allele model.
Results: The analysis included 14 articles reporting 16 studies involving 3265 MS patients and 3735 healthy controls. There was no substantial heterogeneity between studies for any of the comparisons. The significance level was not reached for the association between rs333 and MS susceptibility.
Conclusion: The findings of this study could not confirm the relationship between the rs333 and susceptibility to multiple sclerosis.
References
Roberts DF and Bates D. The genetic contribution to multiple sclerosis. Evidence from North-East England. J Neurol Sci. 1982;54(2):287-93. doi: 10.1016/0022-510x(82)90189-7.
Westerlind H, Ramanujam R, Uvehag D, Kuja-Halkola R, Boman M, Bottai M, et al. Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain. 2014;137(Pt 3):770-8. doi: 10.1093/brain/awt356.
Fagnani C, Neale MC, Nisticò L, Stazi MA, Ricigliano VA, Buscarinu MC, et al. Twin studies in multiple sclerosis: A meta-estimation of heritability and environmentality. Mult Scler. 2015 Oct;21(11):1404-13. doi: 10.1177/1352458514564492.
Boles GS, Hillert J, Ramanujam R, Westerlind H, Olsson T, Kockum I, et al. The familial risk and heritability of multiple sclerosis and its onset phenotypes: A case-control study. Mult Scler. 2023 Sep;29(10):1209-15. doi: 10.1177/13524585231185258.
Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996;35(11):3362-7. doi: 10.1021/bi952950g.
Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996 Aug 9;86(3):367-77. doi: 10.1016/s0092-8674(00)80110-5.
Dean M, Carrington M, O'Brien SJ. Balanced polymorphism selected by genetic versus infectious human disease. Annu Rev Genomics Hum Genet. 2002;3:263-92. doi: 10.1146/annurev.genom.3.022502.103149.
Solloch UV, Lang K, Lange V, Böhme I, Schmidt AH, Sauter J. Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers. Hum Immunol. 2017;78(11-12):710-7. doi: 10.1016/j.humimm.2017.10.001.
Dieter C, Brondani LA, Leitão CB, Gerchman F, Lemos NE, Crispim D. Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis. PLoS One. 2022;17(7):e0270627. doi: 10.1016/j.humimm.2017.10.001.
Saadat M. COVID-19 prevalence and mortality is associated with the allele frequency of CCR5-Δ32. Croat Med J. 2021;62(3):303-4. doi: 10.3325/cmj.2021.62.303.
Starcevic Cizmarevic N, Kapovic M, Roncevic D, Ristic S. Could the CCR5-Delta32 mutation be protective in SARS-CoV-2 infection? Physiol Res. 2021;70(S2):S249-52. doi: 10.33549/physiolres.934725.
Gupta K, Kaur G, Pathak T, Banerjee I. Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severity. Gene. 2022;844:146790. doi: 10.1016/j.gene.2022.146790.
Mlicka D, Duleba A, Czajkowski R, Gawrych M, Woźniacka A, Robak E, et al. Variability of the rs333 in Polish patients with lupus erythematosus. Postepy Dermatol Alergol. 2021 Feb;38(2):131-6. doi: 10.5114/ada.2021.104288.
Lee YH, Kim JH, Song GG. Chemokine receptor 5 Δ32 polymorphism and systemic lupus erythematosus, vasculitis, and primary Sjogren's syndrome. Meta-analysis of possible associations. Z Rheumatol. 2014;73(9):848-55. doi: 10.1007/s00393-014-1356-5.
Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med. 2008 Dec 25;359(26):2767-77. doi: 10.1056/NEJMoa0807917.
Song GG, Kim JH, Lee YH. The chemokine receptor 5 delta32 polymorphism and type 1 diabetes, Behcet's disease, and asthma: a meta-analysis. Immunol Invest. 2014;43(2):123-36. doi: 10.3109/08820139.2013.847457.
Cooke SP, Forrest G, Venables PJ, Hajeer A. The delta32 deletion of CCR5 receptor in rheumatoid arthritis. Arthritis Rheum. 1998;41(6):1135-6. doi: 10.1002/1529-0131(199806)41:6<1135::AID-ART24>3.0.CO;2-N.
Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol. 1997;58(1):52-9. doi: 10.1016/s0198-8859(97)00207-3.
Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol. 2000;102(1):98-106. doi: 10.1016/s0165-5728(99)00166-6.
Favorova OO, Andreewski TV, Boiko AN, Sudomoina MA, Alekseenkov AD, Kulakova OG, et al. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology. 2002 Nov 26;59(10):1652-5. doi: 10.1212/01.wnl.0000035626.92372.0a.
Luomala M, Lehtimäki T, Huhtala H, Ukkonen M, Koivula T, Hurme M, et al. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand. 2003 Dec;108(6):396-400. doi: 10.1034/j.1600-0404.2003.00165.x.
Gade-Andavolu R, Comings DE, MacMurray J, Rostamkhani M, Cheng LS, Tourtellotte WW, et al. Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet Med. 2004 May-Jun;6(3):126-31. doi: 10.1097/01.gim.0000127274.45301.54.
Pulkkinen K, Luomala M, Kuusisto H, Lehtimäki T, Saarela M, Jalonen TO, et al. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol Scand. 2004 May;109(5):342-7. doi: 10.1046/j.1600-0404.2003.00233.x.
Silversides JA, Heggarty SV, McDonnell GV, Hawkins SA, Graham CA. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler. 2004;10(2):149-52. doi: 10.1191/1352458504ms994oa.
Ristić S, Lovrecić L, Starcević-Cizmarević N, Brajenović-Milić B, Jazbec SS, Barac-Latas V, et al. No association of CCR5delta32 gene mutation with multiple sclerosis in Croatian and Slovenian patients. Mult Scler. 2006 Jun;12(3):360-2. doi: 10.1191/135248506ms1305sr.
Kaimen-Maciel DR, Reiche EM, Brum Souza DG, Frota Comini ER, Bobroff F, Morimoto HK, et al. CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis. Int J Mol Med. 2007 Sep;20(3):337-44. PMID: 17671738.
Sellebjerg F, Kristiansen TB, Wittenhagen P, Garred P, Eugen-Olsen J, Frederiksen JL, et al. Chemokine receptor CCR5 in interferon-treated multiple sclerosis. Acta Neurol Scand. 2007 Jun;115(6):413-8. doi: 10.1111/j.1600-0404.2007.00826.x.
van Veen T, Nielsen J, Berkhof J, Barkhof F, Kamphorst W, Bö L, et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol. 2007 Oct;190(1-2):157-64. doi: 10.1016/j.jneuroim.2007.08.005.
Otaegui D, Ruíz-Martínez J, Olaskoaga J, Emparanza JI, López de Munain A. Influence of CCR5-Delta32 genotype in Spanish population with multiple sclerosis. Neurogenetics 2007;8(3):201-5. doi: 10.1007/s10048-007-0085-1.
Shahbazi M, Ebadi H, Fathi D, Roshandel D, Mahamadhoseeni M, Rashidbaghan A, et al. CCR5-delta 32 allele is associated with the risk of developing multiple sclerosis in the Iranian population. Cell Mol Neurobiol. 2009 Dec;29(8):1205-9. doi: 10.1007/s10571-009-9415-1.
Kazemi Arababadi M, Hassanshahi G, Azin H, Salehabad VA, Araste M, Pourali R, et al. No association between CCR5-Δ32 mutation and multiple sclerosis in patients of South eastern Iran. Lab Med. 2010;41(1):31-3. doi: 10.1309/LM9TU9ID1CGZVLXL.
D'Angelo R, Crisafulli C, Rinaldi C, Ruggeri A, Amato A, Sidoti A. CCR5Δ32 polymorphism associated with a slower rate disease progression in a cohort of RR-MS Sicilian patients. Mult Scler Int. 2011;2011:153282. doi: 10.1155/2011/153282.
Török N, Molnár K, Füvesi J, Karácsony M, Zsiros V, Fejes-Szabó A, et al. Chemokine receptor V Δ32 deletion in multiple sclerosis patients in Csongrád County in Hungary and the North-Bácska region in Serbia. Hum Immunol. 2015 Jan;76(1):59-64. doi: 10.1016/j.humimm.2014.11.001.
Karam RA, Rezk NA, Amer MM, Fathy HA. Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy. IUBMB Life. 2016;68(9):727-34. doi: 10.1002/iub.1530.
Troncoso LL, Pontillo A, Oliveira EML, Finkelszteijn A, Schneider S, Chies JAB. CCR5Δ32 - A piece of protection in the inflammatory puzzle of multiple sclerosis susceptibility. Hum Immunol. 2018;79(8):621-6. doi: 10.1016/j.humimm.2018.04.015.
Asgharzadeh M, Sanajoo D, Mahdavi Poor B, Samadi Kafil H, Gholizadeh P, Rashedi J. Interleukin-10 promoter and the CCR5 polymorphisms in Iranian Azari population with multiple sclerosis. Iran J Immunol. 2021;18(3):241-8. doi: 10.22034/iji.2021.83883.1634.
Song GG, Lee YH. A Meta-analysis of the relation between chemokine receptor 5 delta32 polymorphism and multiple sclerosis susceptibility. Immunol Invest. 2014;43(4):299-311. doi: 10.3109/08820139.2013.845204.
Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE Statement. Ann Intern Med. 2009 Feb 3;150(3):206-15. doi: 10.7326/0003-4819-150-3-200902030-00011.
Saadat M. Evaluation of Hardy-Weinberg equilibrium in genetic association studies. Int J Immunogenet. 2024;51:183-6. doi: 10.1111/iji.12668.
Saadat M. The importance of examining the Hardy-Weinberg Equilibrium in genetic association studies. Mol Biol Res Commun. 2024;13:1-2. doi: 10.22099/mbrc.2023.48386.1872.
Ye J, Li XF, Wang YD, Yuan Y. Arg72Pro polymorphism of TP53 gene and the risk of skin cancer: a meta-analysis. PLoS One. 2013;8(11):e79983. doi: 10.1371/journal.pone.0079983.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. doi: 10.1016/0197-2456(86)90046-2.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48. PMID: 13655060.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep 13;315(7109):629-34. doi: 10.1136/bmj.315.7109.629.
Gharagozloo M, Doroudchi M, Farjadian S, Pezeshki AM, Ghaderi A. The frequency of CCR5Delta32 and CCR2-64I in southern Iranian normal population. Immunol Lett. 2005;96(2):277-81. doi: 10.1016/j.imlet.2004.09.007.
Donyavi T, Bokharaei-Salim F, Nahand JS, Garshasbi S, Esghaei M, Sadeghi M, et al. Evaluation of CCR5-Δ32 mutation among individuals with high risk behaviors, neonates born to HIV-1 infected mothers, HIV-1 infected individuals, and healthy people in an Iranian population. J Med Virol. 2020 Aug;92(8):1158-64. doi: 10.1002/jmv.25658.
Lee YH, Bae SC, Song GG. Association between the chemokine receptor 5 delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Mod Rheumatol. 2013;23(2):304-10. doi: 10.1007/s10165-012-0665-2.
Ortiz-Fernández L, García-Lozano JR, Montes-Cano MA, Conde-Jaldón M, Ortego-Centeno N, Castillo-Palma MJ, et al. Association of CCR5Δ32 and Behçet's disease: new data from a case-control study in the Spanish population and meta-analysis. Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S96-100. PMID: 26393284.
Barcellos LF, Schito AM, Rimmler JB, Vittinghoff E, Shih A, Lincoln R, et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics. 2000 Apr;51(4-5):281-8. doi: 10.1007/s002510050621.
Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology. 2003;61(2):238-40. doi: 10.1212/01.wnl.0000069921.20347.9e.
Saadat I and Saadat M. Autoimmune diseases share a common genetic architecture involving the JAK-STAT pathway. EXCLI J. 2024;23:1027-9. doi: 10.17179/excli202
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).